SGEN
- Seagen Inc.
()
Overview
Company Summary
Seagen Inc. (formerly Seattle Genetics) is a global biotechnology company based in Bothell, Washington. The company is focused on developing and commercializing innovative antibody-based therapies for the treatment of cancer.
Seagen's primary product is ADCETRIS� (brentuximab vedotin), which is an antibody-drug conjugate (ADC) designed to selectively target cancer cells and deliver a potent cytotoxic agent to kill those cells. ADCETRIS� is approved for the treatment of several types of lymphomas and is being further investigated for additional indications.
The company's main area of expertise lies in its proprietary ADC technology platform, known as ADCETRIS� or ADC technology. This platform enables the development of ADCs by utilizing monoclonal antibodies that are linked to potent cytotoxic agents. These ADCs are designed to specifically target cancer cells, delivering the cytotoxic agent directly to the cancerous cells while minimizing damage to healthy cells surrounding the tumor.
Seagen utilizes its technology platform to develop a robust pipeline of potential new treatments for various types of cancer. The company is actively involved in researching and developing novel ADCs, as well as exploring additional indications for existing therapies.
Through collaborations with pharmaceutical and biotech partners, Seagen also seeks to expand the application of its technology into areas beyond oncology, potentially addressing other diseases such as autoimmune disorders.
In summary, Seagen Inc. is a biotechnology company specializing in the development and commercialization of antibody-drug conjugates for the treatment of cancer, with a strong focus on innovation and the potential expansion of its technology into other therapeutic areas.